Imatinib Mesylate and 17-N-Allylamino-17-Demethoxygeldanamycin in Treating Patients With Chronic Myelogenous Leukemia

You may be eligible if

• DISEASE CHARACTERISTICS:
• Diagnosis of chronic myelogenous leukemia, including any of the following phases:
• * Blastic phase
• * Greater than 30% blasts in the peripheral blood or bone marrow
• * Previously untreated disease OR refractory to or relapsed after most recent therapy
• * Accelerated phase, defined by 1 of the following:
• * At least 15, but less than 30%, blasts in the peripheral blood or bone marrow
• * At least 30% blasts and promyelocytes in the peripheral blood or bone marrow
• * Greater than 20% peripheral blood basophilia
• * Chronic phase
• * No major cytogenetic response (less than 65% Philadelphia chromosome negative) after 12 months of prior imatinib mesylate therapy
• Philadelphia chromosome positive by routine cytogenetics
• PATIENT CHARACTERISTICS:
• Age
• 18 and over
• Performance status
• ECOG 0-2
• Life expectancy
• At least 3 months
• Hematopoietic
• Not specified
• Hepatic
• Bilirubin no greater than 1.5 mg/dL
• ALT and AST no greater than 2.5 times upper limit of normal
• Renal
• Creatinine less than 1.5 mg/dL
• Cardiovascular
• No symptomatic congestive heart failure
• No unstable angina pectoris
• No cardiac arrhythmia
• Other
• Not pregnant or nursing
• Negative pregnancy test
• Fertile patients must use effective contraception
• No known allergy to eggs
• Able to swallow pills
• No ongoing or active infection
• No psychiatric illness or social situation that would preclude study compliance
• No other concurrent uncontrolled medical illness
• PRIOR CONCURRENT THERAPY:
• Biologic therapy
• No prior stem cell transplantation
• Chemotherapy
• More than 4 weeks since prior chemotherapy (except hydroxyurea or anagrelide) (at least 6 weeks for nitrosoureas or mitomycin)
• Endocrine therapy
• Not specified
• Radiotherapy
• More than 4 weeks since prior radiotherapy
• Surgery
• No prior liver, kidney, or lung transplantation
• More than 14 days since prior major surgery (e.g., thoracotomy or intra-abdominal surgery)
• Other
• Prior imatinib mesylate administered within the past 4 weeks is allowed
• No concurrent tacrolimus or cyclosporine as immunosuppressive agents
• No other concurrent investigational agents
• No concurrent combination antiretroviral therapy for HIV-positive patients
• No concurrent agents that alter CYP3A4 activity, including any of the following:
• * Grapefruit juice
• * Ketoconazole
• * Fluconazole
• * Itraconazole
• * Erythromycin
• * Clarithromycin
• * Cimetidine
• * Terfenadine
• * Astemizole
• * HIV protease inhibitors (e.g., indinavir and nelfinavir)